SynthesisJournal of neurology2026
Associations between duration of status epilepticus and clinical outcomes in adults: a systematic review.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDuration of status epilepticus (SE) is widely considered a key determinant of outcome severity, but its prognostic value is hard to interpret because definitions of seizure onset, termination, and recurrence, as well as analytical handling, differ substantially across studies. We reviewed its association with mortality, functional outcome (motor and/or cognitive impairment), and refractoriness in adults.
methodsWe searched MEDLINE (via PubMed), Cochrane CENTRAL, and Scopus for studies examining SE duration in relation to clinical outcomes in adults. We extracted study design, SE phenotype, duration definitions, analytical strategy, and temporal thresholds. Risk of bias was assessed with the QUIPS tool. Outcome-specific associations were synthesized narratively.
resultsForty-three studies (1994-2025) were included. The definitions and measurement of SE duration, as well as analytical approaches (continuous vs. categorical, with heterogeneous thresholds), varied widely. Mortality was assessed in 31 studies, functional outcome in 26, and refractoriness in 7. Longer duration was more consistently and independently associated with worse functional outcome than with mortality; the weaker mortality signal likely reflects competing determinants such as etiology, premorbid vulnerability, and systemic severity. The evidence on refractoriness was limited but consistent with a link between prolonged seizures and treatment resistance.
conclusionsSE duration should be interpreted as a context-dependent prognostic marker rather than as an absolute threshold. Its meaning appears to be shaped by the specific outcome, electroclinical phenotype, etiology, and diagnostic approach. Standardized onset and termination criteria, explicit recurrence rules, and harmonized modeling would improve cross-study comparability and strengthen prognostic assessment.
Indexed as
Identifiers
42836884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.